The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease
Open accessAbstract
A comprehensive, unbiased inventory of synuclein forms present in Lewy bodies from patients with dementia with Lewy bodies was carried out using two-dimensional immunoblot analysis, novel sandwich enzyme-linked immunosorbent assays with modification-specific synuclein antibodies, and mass spectroscopy. The predominant modification of alpha-synuclein in Lewy bodies is a single phosphorylation at Ser-129. In addition, there is a set of characteristic modifications that are present to a lesser extent, including ubiquitination at Lys residues 12, 21, and 23 and specific truncations at Asp-115, Asp-119, Asn-122, Tyr-133, and Asp-135. No other modifications are detectable by tandem mass spectrometry mapping, except for a ubiquitous N-terminal acetylation. Small amounts of Ser-129 phosphorylated and Asp-119-truncated alpha-synuclein are present in the soluble fraction of both normal and disease brains, suggesting that these Lewy body-associated forms are produced during normal metabolism of alpha-synuclein. In contrast, ubiquitination is only detected in Lewy bodies and is primarily present on phosphorylated synuclein; it therefore likely occurs after phosphorylated synuclein has deposited into Lewy bodies. This invariant pattern of specific phosphorylation, truncation, and ubiquitination is also present in the detergent-insoluble fraction of brain from patients with familial Parkinson's disease (synuclein A53T mutation) as well as multiple system atrophy, suggesting a common pathogenic pathway for both genetic and sporadic Lewy body diseases. These observations are most consistent with a model in which preferential accumulation of normally produced Ser-129 phosphorylated alpha-synuclein is the key event responsible for the formation of Lewy bodies in various Lewy body diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
α-Synuclein is phosphorylated in synucleinopathy lesions
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., & Iwatsubo, T. (2002) · Nature Cell Biology · doi:10.1038/ncb748 · Cited by 2,132
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Protein regulation by monoubiquitin
Hicke, L. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35056583 · Cited by 1,211
Identification of two distinct synucleins from human brain
Jakes, R., Spillantini, M. G., & Goedert, M. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00395-5 · Cited by 1,080
Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease
Ibáñez, P., Bonnet, A.-M., Débarges, B., Lohmann, E., Tison, F., Agid, Y., Dürr, A., Brice, A., & Pollak, P. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17104-3 · Cited by 1,044
Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation
Serpell, L. C., Berriman, J., Jakes, R., Goedert, M., & Crowther, R. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4897 · Cited by 748
Cited by
Li, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., Lashley, T., Quinn, N. P., Rehncrona, S., Björklund, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1746 · Cited by 1,845
Ubiquitination in disease pathogenesis and treatment
Popovic, D., Vucic, D., & Dikic, I. (2014) · Nature Medicine · doi:10.1038/nm.3739 · Cited by 1,401
Kim, S., Kwon, S.-H., Kam, T.-I., Panicker, N., Karuppagounder, S. S., Lee, S., Lee, J. H., Kim, W. R., Kook, M., Foss, C. A., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.05.035 · Cited by 1,397
“Themajority of a-syn in fibrils and in LBs is phosphorylated on serine 129 (pSer129-a-syn) (Anderson et al., 2006; Fujiwara et al., 2002).”
BackgroundGoedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190
Roles of tau protein in health and disease
Guo, T., Noble, W., & Hanger, D. P. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1707-9 · Cited by 1,003
T cells from patients with Parkinson’s disease recognize α-synuclein peptides
Sulzer, D., Alcalay, R. N., Garretti, F., Cote, L., Kanter, E., Agin-Liebes, J., Liong, C., McMurtrey, C., Hildebrand, W. H., Mao, X., et al. (2017) · Nature · doi:10.1038/nature22815 · Cited by 866
Mahul-Mellier, A.-L., Burtscher, J., Maharjan, N., Weerens, L., Croisier, M., Kuttler, F., Leleu, M., Knott, G. W., & Lashuel, H. A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913904117 · Cited by 710
Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease
Rocha, E. M., De Miranda, B., & Sanders, L. H. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.04.004 · Cited by 762
α-Synuclein misfolding and Parkinson's disease
Breydo, L., Wu, J. W., & Uversky, V. N. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.002 · Cited by 657
What Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease
Corti, O., Lesage, S., & Brice, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00022.2010 · Cited by 611
Cryo-EM structure of alpha-synuclein fibrils
Guerrero-Ferreira, R., Taylor, N. M., Mona, D., Ringler, P., Lauer, M. E., Riek, R., Britschgi, M., & Stahlberg, H. (2018) · eLife · doi:10.7554/elife.36402 · Cited by 600
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Self-citationCell Biology and Pathophysiology of α-Synuclein
Burré, J., Sharma, M., & Südhof, T. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024091 · Cited by 579
The Synucleinopathies: Twenty Years On
Goedert, M., Jakes, R., & Spillantini, M. G. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-179005 · Cited by 569
Fauvet, B., Mbefo, M. K., Fares, M.-B., Desobry, C., Michael, S., Ardah, M. T., Tsika, E., Coune, P., Prudent, M., Lion, N., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.318949 · Cited by 566
Protein Aggregation in the Brain: The Molecular Basis for Alzheimer’s and Parkinson’s Diseases
Irvine, G. B., El-Agnaf, O. M., Shankar, G. M., & Walsh, D. M. (2008) · Molecular Medicine · doi:10.2119/2007-00100.irvine · Cited by 550
Lee, W.-H., Loo, C.-Y., Bebawy, M., Luk, F., Mason, R., & Rohanizadeh, R. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311040002 · Cited by 537
Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction
Tai, H.-C., & Schuman, E. M. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2499 · Cited by 532
Dehay, B., Bourdenx, M., Gorry, P., Przedborski, S., Vila, M., Hunot, S., Singleton, A., Olanow, C. W., Merchant, K. M., Bezard, E., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00006-x · Cited by 529
Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood
Barbour, R., Kling, K., Anderson, J. P., Banducci, K., Cole, T., Diep, L., Fox, M., Goldstein, J. M., Soriano, F., Seubert, P., et al. (2008) · Neurodegenerative Diseases · doi:10.1159/000112832 · Cited by 527
Self-citationSystemic exosomal siRNA delivery reduced alpha‐synuclein aggregates in brains of transgenic mice
Cooper, J. M., Wiklander, P. B. O., Nordin, J. Z., Al‐Shawi, R., Wood, M. J., Vithlani, M., Schapira, A. H. V., Simons, J. P., El‐Andaloussi, S., & Alvarez‐Erviti, L. (2014) · Movement Disorders · doi:10.1002/mds.25978 · Cited by 507
Physicochemical Properties of Cells and Their Effects on Intrinsically Disordered Proteins (IDPs)
Theillet, F.-X., Binolfi, A., Frembgen-Kesner, T., Hingorani, K., Sarkar, M., Kyne, C., Li, C., Crowley, P. B., Gierasch, L., Pielak, G. J., et al. (2014) · Chemical Reviews · doi:10.1021/cr400695p · Cited by 503
The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma.
Ramirez, A. I., de Hoz, R., Salobrar-Garcia, E., Salazar, J. J., Rojas, B., Ajoy, D., López-Cuenca, I., Rojas, P., Triviño, A., & Ramírez, J. M. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00214 · Cited by 466
Jang, H., Boltz, D., Sturm-Ramirez, K., Shepherd, K. R., Jiao, Y., Webster, R., & Smeyne, R. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900096106 · Cited by 459
Lebouvier, T., Neunlist, M., Bruley des Varannes, S., Coron, E., Drouard, A., N'Guyen, J.-M., Chaumette, T., Tasselli, M., Paillusson, S., Flamand, M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012728 · Cited by 427
α-Synuclein and neuronal cell death
Cookson, M. R. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-9 · Cited by 418
Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles
Meade, R. M., Fairlie, D. P., & Mason, J. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0329-1 · Cited by 404
Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.06.004 · Cited by 382
Self-citationOueslati, A. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160779 · Cited by 375
Alpha-synuclein biology in Lewy body diseases
Kim, W. S., Kågedal, K., & Halliday, G. M. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0073-2 · Cited by 374
Karve, T. M., & Cheema, A. K. (2011) · Journal of Amino Acids · doi:10.4061/2011/207691 · Cited by 364
Paleologou, K. E., Schmid, A. W., Rospigliosi, C. C., Kim, H.-Y., Lamberto, G. R., Fredenburg, R. A., Lansbury, P. T., Fernandez, C. O., Eliezer, D., Zweckstetter, M., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800747200 · Cited by 363
A Pathologic Cascade Leading to Synaptic Dysfunction in -Synuclein-Induced Neurodegeneration
Scott, D. A., Tabarean, I., Tang, Y., Cartier, A., Masliah, E., & Roy, S. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1091-10.2010 · Cited by 353
Oueslati, A., Fournier, M., & Lashuel, H. A. (2010) · Progress in Brain Research · doi:10.1016/s0079-6123(10)83007-9 · Cited by 347
Gangliosides in the Brain: Physiology, Pathophysiology and Therapeutic Applications
Sipione, S., Monyror, J., Galleguillos, D., Steinberg, N., & Kadam, V. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.572965 · Cited by 325
Paleologou, K. E., Oueslati, A., Shakked, G., Rospigliosi, C. C., Kim, H.-Y., Lamberto, G. R., Fernandez, C. O., Schmid, A., Chegini, F., Gai, W. P., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5922-09.2010 · Cited by 324
Self-citationα‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities
Alam, P., Bousset, L., Melki, R., & Otzen, D. E. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14808 · Cited by 307
Sevlever, D., Jiang, P., & Yen, S.-H. C. (2008) · Biochemistry · doi:10.1021/bi800699v · Cited by 305
Cullen, V., Sardi, S. P., Ng, J., Xu, Y., Sun, Y., Tomlinson, J. J., Kolodziej, P., Kahn, I., Saftig, P., Woulfe, J., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22400 · Cited by 303
Self-citationA natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity
Perni, M., Galvagnion, C., Maltsev, A., Meisl, G., Müller, M. B. D., Challa, P. K., Kirkegaard, J. B., Flagmeier, P., Cohen, S. I. A., Cascella, R., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610586114 · Cited by 298
Gorbatyuk, O. S., Li, S., Sullivan, L. F., Chen, W., Kondrikova, G., Manfredsson, F. P., Mandel, R. J., & Muzyczka, N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711053105 · Cited by 293
Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo
Periquet, M., Fulga, T., Myllykangas, L., Schlossmacher, M. G., & Feany, M. B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0285-07.2007 · Cited by 292
Self-citationFanning, S., Haque, A., Imberdis, T., Baru, V., Barrasa, M. I., Nuber, S., Termine, D., Ramalingam, N., Ho, G. P. H., Noble, T., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.11.028 · Cited by 285
“In humans, increased aS phosphorylation is associated with fPD (Lesage et al., 2013), DLB (Obi et al., 2008), and increased pathological severity of idiopathic PD (Anderson et al., 2006; Walker et al., 2013).”
Backgroundα-Synuclein and dopamine at the crossroads of Parkinson's disease
Venda, L. L., Cragg, S. J., Buchman, V. L., & Wade-Martins, R. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.09.004 · Cited by 285
A Role for Neuronal Alpha-Synuclein in Gastrointestinal Immunity
Stolzenberg, E., Berry, D., Yang, D., Lee, E. Y., Kroemer, A., Kaufman, S., Wong, G. C. L., Oppenheim, J. J., Sen, S., Fishbein, T., et al. (2017) · Journal of Innate Immunity · doi:10.1159/000477990 · Cited by 284
Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo
Cullen, V., Lindfors, M., Ng, J., Paetau, A., Swinton, E., Kolodziej, P., Boston, H., Saftig, P., Woulfe, J., Feany, M. B., et al. (2009) · Molecular Brain · doi:10.1186/1756-6606-2-5 · Cited by 279
Self-citationOligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
Majbour, N. K., Vaikath, N. N., van Dijk, K. D., Ardah, M. T., Varghese, S., Vesterager, L. B., Montezinho, L. P., Poole, S., Safieh-Garabedian, B., Tokuda, T., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0072-9 · Cited by 277
Ubiquitin ligase Nedd4 promotes α-synuclein degradation by the endosomal–lysosomal pathway
Tofaris, G. K., Kim, H. T., Hourez, R., Jung, J.-W., Kim, K. P., & Goldberg, A. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109356108 · Cited by 271
The ongoing pursuit of neuroprotective therapies in Parkinson disease
Athauda, D., & Foltynie, T. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.226 · Cited by 269
Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity
Qiao, L., Hamamichi, S., Caldwell, K. A., Caldwell, G. A., Yacoubian, T. A., Wilson, S., Xie, Z.-L., Speake, L. D., Parks, R., Crabtree, D., et al. (2008) · Molecular Brain · doi:10.1186/1756-6606-1-17 · Cited by 263
Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease
Alecu, I., & Bennett, S. A. L. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00328 · Cited by 258
Osterberg, V. R., Spinelli, K. J., Weston, L. J., Luk, K. C., Woltjer, R. L., & Unni, V. K. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.060 · Cited by 256
Protein phosphorylation in neurodegeneration: friend or foe?
Tenreiro, S., Eckermann, K., & Outeiro, T. F. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00042 · Cited by 252
Uchihara, T., & Giasson, B. I. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1485-1 · Cited by 249
“Figure 1) as this residue is highly phosphorylated in human pathological inclusions (~90 % phosphorylated in inclusions versus ~4 % phosphorylated in total brain αS) [3, 24, 59, 187], phosphorylated Ser 129 (pSer129) immunoreactivity on histological sections should not be equated to the formation of αS inclusion witho…”
Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease
Allen Reish, H. E., & Standaert, D. G. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-140491 · Cited by 244
Tau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies
Sinsky, J., Pichlerova, K., & Hanes, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179207 · Cited by 220
“Proteolytic cleavage of specific proteins is the common denominator of many neurodegenerative diseases including huntingtin protein in Huntington’s disease [386,387], α-synuclein in Parkinson’s disease and Lewy body dementia [388], ataxins in cerebral ataxia [389,390], prion protein in prionosis [391,392] and tau”
BackgroundOliveras-Salvá, M., Van der Perren, A., Casadei, N., Stroobants, S., Nuber, S., D’Hooge, R., Van den Haute, C., & Baekelandt, V. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-44 · Cited by 191
Ghanem, S. S., Majbour, N. K., Vaikath, N. N., Ardah, M. T., Erskine, D., Jensen, N. M., Fayyad, M., Sudhakaran, I. P., Vasili, E., Melachroinou, K., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2109617119 · Cited by 191
Kellie, J. F., Higgs, R. E., Ryder, J. W., Major, A., Beach, T. G., Adler, C. H., Merchant, K., & Knierman, M. D. (2014) · Scientific Reports · doi:10.1038/srep05797 · Cited by 182
Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts
Fellner, L., Jellinger, K. A., Wenning, G. K., & Stefanova, N. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0833-z · Cited by 162
“Post-translational modifications of a-synuclein, including nitration, glycosylation, phosphorylation and ubiquitination are commonly described in relation to pathological accumulation of the protein and may contribute to the pathogenesis of PD, DLB and MSA [6, 73, 74, 239].”
BackgroundZhang, Q.-S., Heng, Y., Yuan, Y.-H., & Chen, N.-H. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2016.11.002 · Cited by 156
Yang, J., Luo, S., Zhang, J., Yu, T., Fu, Z., Zheng, Y., Xu, X., Liu, C., Fan, M., & Zhang, Z. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105218 · Cited by 152
Tóth, G., Gardai, S. J., Zago, W., Bertoncini, C. W., Cremades, N., Roy, S. L., Tambe, M. A., Rochet, J.-C., Galvagnion, C., Skibinski, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087133 · Cited by 151
Self-citationPérez-Revuelta, B. I., Hettich, M. M., Ciociaro, A., Rotermund, C., Kahle, P. J., Krauss, S., & Di Monte, D. A. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.175 · Cited by 140
Casein kinase 1α: biological mechanisms and theranostic potential
Jiang, S., Zhang, M., Sun, J., & Yang, X. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0236-z · Cited by 130
(2023) · doi:10.1016/j.neuron.2023.11.020 · Cited by 127
Tapias, V., Hu, X., Luk, K. C., Sanders, L. H., Lee, V. M., & Greenamyre, J. T. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2541-x · Cited by 126
Deubiquitinase Usp8 regulates α-synuclein clearance and modifies its toxicity in Lewy body disease
Alexopoulou, Z., Lang, J., Perrett, R. M., Elschami, M., Hurry, M. E. D., Kim, H. T., Mazaraki, D., Szabo, A., Kessler, B. M., Goldberg, A. L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1523597113 · Cited by 125
Guerrero, E., Vasudevaraju, P., Hegde, M. L., Britton, G. B., & Rao, K. S. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8328-z · Cited by 121
Aso, E., Lomoio, S., López‐González, I., Joda, L., Carmona, M., Fernández‐Yagüe, N., Moreno, J., Juvés, S., Pujol, A., Pamplona, R., et al. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00560.x · Cited by 118
Lou, H., Montoya, S. E., Alerte, T. N. M., Wang, J., Wu, J., Peng, X., Hong, C.-S., Friedrich, E. E., Mader, S. A., Pedersen, C. J., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100867 · Cited by 115
Jiang, P., Gan, M., Yen, S.-H., McLean, P. J., & Dickson, D. W. (2017) · Scientific Reports · doi:10.1038/s41598-017-08149-w · Cited by 115
SGK1 inhibition in glia ameliorates pathologies and symptoms in Parkinson disease animal models
Kwon, O., Song, J., Yang, Y., Kim, S., Kim, J. Y., Seok, M., Hwang, I., Yu, J., Karmacharya, J., Maeng, H., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013076 · Cited by 110
T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease
Williams, G. P., Marmion, D. J., Schonhoff, A. M., Jurkuvenaite, A., Won, W.-J., Standaert, D. G., Kordower, J. H., & Harms, A. S. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02126-w · Cited by 102
“Similar to results obtained in rats and nonhuman primates [37], mice transduced with Olig001-SYN displayed robust positive staining for pSer129, an α-syn residue modification selectively and extensively observed in neuronal or glial synucleinopathies [2, 21], while control Olig001-GFP injected mice did not (Fig.”
ResultPathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies
Kawahata, I., Finkelstein, D. I., & Fukunaga, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116216 · Cited by 102
Szego, E. M., Malz, L., Bernhardt, N., Rösen-Wolff, A., Falkenburger, B. H., & Luksch, H. (2022) · eLife · doi:10.7554/elife.81943 · Cited by 94
Bantle, C. M., Phillips, A. T., Smeyne, R. J., Rocha, S. M., Olson, K. E., & Tjalkens, R. B. (2019) · npj Parkinson's Disease · doi:10.1038/s41531-019-0090-8 · Cited by 89
The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases
Rozpędek-Kamińska, W., Siwecka, N., Wawrzynkiewicz, A., Wojtczak, R., Pytel, D., Diehl, J. A., & Majsterek, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062108 · Cited by 84
Sorrentino, Z. A., Brooks, M. M. T., Hudson, V., Rutherford, N. J., Golde, T. E., Giasson, B. I., & Chakrabarty, P. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0182-z · Cited by 79
Refolo, V., Bez, F., Polissidis, A., Kuzdas-Wood, D., Sturm, E., Kamaratou, M., Poewe, W., Stefanis, L., Angela Cenci, M., Romero-Ramos, M., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0504-y · Cited by 67
Herman, S., Djaldetti, R., Mollenhauer, B., & Offen, D. (2023) · Brain · doi:10.1093/brain/awac261 · Cited by 62
Triplett, J. C., Zhang, Z., Sultana, R., Cai, J., Klein, J. B., Büeler, H., & Butterfield, D. A. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13039 · Cited by 58
Kleinknecht, A., Popova, B., Lázaro, D. F., Pinho, R., Valerius, O., Outeiro, T. F., & Braus, G. H. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006098 · Cited by 58
Majbour, N. K., Chiasserini, D., Vaikath, N. N., Eusebi, P., Tokuda, T., van de Berg, W., Parnetti, L., Calabresi, P., & El-Agnaf, O. M. A. (2017) · Scientific Reports · doi:10.1038/srep40263 · Cited by 55
Bencsik, A., Muselli, L., Leboidre, M., Lakhdar, L., & Baron, T. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000137 · Cited by 48
Kaneko, H., Kakita, A., Kasuga, K., Nozaki, H., Ishikawa, A., Miyashita, A., Kuwano, R., Ito, G., Iwatsubo, T., Takahashi, H., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4244-07.2007 · Cited by 44
Matsuo, K., Cheng, A., Yabuki, Y., Takahata, I., Miyachi, H., & Fukunaga, K. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.03.029 · Cited by 43
Cerebrospinal fluid α‐synuclein contributes to the differential diagnosis of Alzheimer's disease
Shi, M., Tang, L., Toledo, J. B., Ginghina, C., Wang, H., Aro, P., Jensen, P. H., Weintraub, D., Chen‐Plotkin, A. S., Irwin, D. J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.015 · Cited by 42
Inflammation kinase PKR phosphorylates α-synuclein and causes α-synuclein-dependent cell death
Reimer, L., Vesterager, L. B., Betzer, C., Zheng, J., Nielsen, L. D., Kofoed, R. H., Lassen, L. B., Bølcho, U., Paludan, S. R., Fog, K., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.03.001 · Cited by 42
Emamzadeh, F. N., Aojula, H., McHugh, P. C., & Allsop, D. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.02.042 · Cited by 42
Immunoreactivity to Lys63-linked polyubiquitin is a feature of neurodegeneration
Paine, S., Bedford, L., Thorpe, J. R., Mayer, R. J., Cavey, J. R., Bajaj, N., Sheppard, P. W., Lowe, J., & Layfield, R. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.05.074 · Cited by 41
Cao, Q., Luo, S., Yao, W., Qu, Y., Wang, N., Hong, J., Murayama, S., Zhang, Z., Chen, J., Hashimoto, K., et al. (2022) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2022.05.037 · Cited by 41
“As demonstrated by various genetic and biochemical studies, a-Syn is the major component of LBs and plays a predominant role in the pathogenesis of PD and DLB.41,42 There is extensive phosphorylation of a-Syn at S129 in LBs.43 Therefore, the most likely hypothesis is that phosphorylation of a-Syn at Ser129 accelerates…”
BackgroundCortical phosphorylated α‐Synuclein levels correlate with brain wave spectra in Parkinson's disease
Caviness, J. N., Lue, L., Hentz, J. G., Schmitz, C. T., Adler, C. H., Shill, H. A., Sabbagh, M. N., Beach, T. G., & Walker, D. G. (2016) · Movement Disorders · doi:10.1002/mds.26621 · Cited by 37
Self-citationIron Redox Chemistry and Implications in the Parkinson’s Disease Brain
Abeyawardhane, D. L., & Lucas, H. R. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/4609702 · Cited by 35
“Such charge pairing can result in electrostatic shielding, which may impact protein folding dynamics by further altering the structure upon protein oxidation, crosslinking, aggregation, etc. Notably, the metal coordination sites for iron and copper are located at opposite termini, where iron preferentially interacts w…”
BackgroundLiu, D., Guo, J.-J., Su, J.-H., Svanbergsson, A., Yuan, L., Haikal, C., Li, W., Gouras, G., & Li, J.-Y. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00242-5 · Cited by 32
Wang, H., Dou, S., Zhu, J., Shao, Z., Wang, C., & Cheng, B. (2020) · Brain Research · doi:10.1016/j.brainres.2020.147023 · Cited by 33
Wang, H., Stewart, T., Toledo, J. B., Ginghina, C., Tang, L., Atik, A., Aro, P., Shaw, L. M., Trojanowski, J. Q., Galasko, D. R., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171013 · Cited by 33
Rivero-Ríos, P., Romo-Lozano, M., Fasiczka, R., Naaldijk, Y., & Hilfiker, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00556 · Cited by 31
Doublecortin-like Kinase 1 Regulates α-Synuclein Levels and Toxicity
Vázquez-Vélez, G. E., Gonzales, K. A., Revelli, J.-P., Adamski, C. J., Alavi Naini, F., Bajić, A., Craigen, E., Richman, R., Heman-Ackah, S. M., Wood, M. J. A., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.1076-19.2019 · Cited by 22
“Importantly, pS129 -Syn is thought to be associated with pathology in humans because it is drastically elevated in the brains of PD patients and in Lewy bodies (Fujiwara et al., 2002; Anderson et al., 2006).”
BackgroundCosden, M., Jinn, S., Yao, L., Gretzula, C. A., Kandebo, M., Toolan, D., Hatcher, N. G., Ma, L., Lemaire, W., Adam, G. C., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105507 · Cited by 23
Metadata
- Authors
- Anderson, J. P., Walker, D. E., Goldstein, J. M., de Laat, R., Banducci, K., Caccavello, R. J., Barbour, R., Huang, J., Kling, K., Lee, M., Diep, L., Keim, P. S., Shen, X., Chataway, T., Schlossmacher, M. G., Seubert, P., Schenk, D., Sinha, S., Gai, W. P., & Chilcote, T. J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-10
- Volume
- 281
- Issue
- 40
- Pages
- 29739-29752
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2108865709
- Cited by
- 1,416
- References
- 36
- FWCI
- 20.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.